Some doctors refuse to purchase cervical cancer vaccine because of low reimbursements

Some physicians are refusing to purchase Merck's cervical cancer vaccine Gardasil or are restricting who receives it because they say insurance reimbursements for the vaccine are too low, the Washington Post reports.

The issue "highlights a long-simmering dispute over reimbursement for immunization" that has "accelerated as the number of costly new vaccines has proliferated," according to the Post . Some insurance companies pay doctors $122 per shot for the three-dose vaccine -- $2 more than the price the physicians pay per dose -- which doctors say is not enough to adequately cover the costs of stocking and administering the vaccine.

The problem disproportionately affects pediatricians, who administer more immunizations and are among the lowest-paid specialists, experts say. Some doctors are providing the vaccine only to those who are insured through plans that will pay a "reasonable" fee for Gardasil, usually about $140 or more per dose. Others write prescriptions for Gardasil, which patients can obtain at pharmacies, and charge a fee for administering the shot. However, many insurers only pay for vaccines provided by a doctor. The "spotty availability" of the vaccine "is likely to complicate efforts by parents to comply" with laws requiring the vaccine for school entry, the Post reports.

Anne Francis, an associate clinical professor of pediatrics at the University of Rochester School of Medicine, noted that the cost of fully immunizing a child has increased from $150 two decades ago to $1,500 today. Francis added that many small practices are reluctant to pay up front for vaccines when it is difficult to make up the cost of even a single lost dose. Merck executives say that the cost of Gardasil is justified by the cost of developing the vaccine and the value it provides. In addition, insurers maintain that they provide adequate reimbursement for the vaccine (Boodman, Washington Post , 5/1).


Kaiser Health NewsThis article was reprinted from khn.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Assessing the impact of gozetotide in PSMA-positive prostate cancer